Angiotensin-converting enzyme inhibition produces electrophysiologic but not antiarrhythmic effects in the intact heart

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 5, 1998, Pages 734-740

  Gilat, Eran ^a,c   Girouard, Steven D ^a   Pastore, Joseph M ^a   Laurita, Kenneth R ^a   Rosenbaum, David S ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Case Western Reserve University   (United States)

^c ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Angiotensin converting enzyme inhibitors; Arrhythmias; Electrophysiology; Enalapril; Reentry; Repolarization

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GUINEA PIG; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; REENTRY ARRHYTHMIA;

ACTION POTENTIALS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARRHYTHMIA; ELECTROPHYSIOLOGY; ENALAPRIL; GUINEA PIGS; HEART; MALE;

EID: 0031976805     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199805000-00012     Document Type: Article

References (36)

1. Pfeffer MA, Braunwald E, Move LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
2. Vannan MA, Webb-Peploe MM, Konstam MA. ACE inhibitors after myocardial infarction. Br Med J 1993;306:531-2.
3. Oldershaw PJ. An overview of survival studies in patients with heart failure. Postgrad Med J 1992;68:606-10.
4. Weber KT, Anversa P, Armstrong PW, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992;20:3-16.
5. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-8.
6. Newman TJ, Maskin CS, Dennick LG, Meyer JH, Hallows BG, Cooper WH. Effects of captopril on survival in patients with heart failure. Am J Med 1988;84:140-4.
7. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
8. Fonarow GC, Chelimsky Fallick C, Stevenson LW, et al. Effect of direct vasodilatation with hydralazine versus angiotensin converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992;19:842-50.
9. Pye MP, Cobbe SM. Mechanisms of ventricular arrhythmias in cardiac failure and hypertrophy. Cardiovasc Res 1992;26:740-50.
10. Webster MW, Fitzpatrick MA, Nicholls MG, Ikram H, Wells JE. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985;56:566-9.
11. Cleland JG, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double blind controlled trial. Br Heart J 1984;52:530-5.
12. Bechler-Lisinska J, Cholewa M, Gorski L, Markiewicz K. Einfluss der Vasodilatatoren auf den Charakter und die Haufigkeit von Herzrhythmusstoningen bei der chronischen Herzinsuffizienz. Z. Gesamte Inn Med 1990;45:71-6.
13. Ambrosioni E, Borghi C, Magnani B. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. Am J Cardiol 1991;68:101-10D.
14. Pomini G, Gribaldo R, Rugna A, Lupia M, Molfese G, Garenza P. Reduction of complex ventricular arrhythmias after enalapril treatment in patients with advanced stable heart failure. G Ital Cardiol 1991:21:59-65.
15. Malerba M, Muiesan ML, Zulu R, Rizzoni D, Calebich S, Agabiti Rosei E, Ventricular arrhythmias and changes in blood pressure and left ventricular mass induced by antihypertensive treatment in hypertensive patients. J Hypertens 1991;9(6):S162-3.
16. Roberti RR, Martinez EE, Andrade JL, et al. Changes cardiomyopathy and captopril. Eur Heart J 1922;13:966-70.
17. Bussmann WD, Micke C, Hildenbrand R, Klepzig H. Captopril bei akutea Herzinfarkt: Einfluss auf infarktgrosse und Rhythmusstorungen. Dtsch Med Wochenschr 1992;177:651-7.
18. Pahor M, Gambassi G, Carbonin P. Antiarrhythmic effects of ACE inhibitors: a matter of faith or reality? Cardiovasc Res 1994;28(2): 173-82.
19. De Mello WC, Crespo MJ, Altieri P. Effect of enalapril on intracellular resistance and conduction velocity in rat ventricular muscle. J Cardiovasc Pharmacol 1993;22(2):259-63.
20. Yang H, Muller-Borer B, Joyhnson T, Lemasters J, Cascio W. Angiotensin II hastens cell-to-cell electrical uncoupling and failure of impulse propagation in ischemic rabbit ventricular muscle. Pacing Clin Electrophysiol 1996;19:644.
21. Rack HF, Koppers D, Lenke P, Casaretto H, Hauswirth O. Fosinoprilat prolongs the action potential: reduction of ik and enhancement of the L-type calcium current in guinea pig ventricular myocytes. Cardiovas Res 1994;28:201-8.
22. Stark G, Stark U, Nagl S, Klein W, Pilger E, Tritthart HA. Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts. Clin Cardiol 1991; 14(7): 579-82.
23. Valenzuela C, Perez O, Casis O, et al. Effects of lisinopril on electromechanical properties and membrane currents in guinea-pig cardiac preparations. Br J Phannacol 1993;109:873-9.
24. Girouard SD, Laurita KR, Rosenbaum DS. Unique properties of cardiac action potentials recorded with voltage-sensitive dyes. J Cardiovasc Electrophysiol 1996;7:1024-38.
25. Girouard SD, Pasture JM, Laurita KR, Gregory KW, Rosenbaum DS. Optical mapping in a new guinea pig model of ventricular tachycardia reveals mechanisms for multiple wavelengths in a single reentrant circuit. Circulation 1996;93:603-13.
26. Rosenbaum DS, Kaplan DR, Kanai A, et al. Repolarization inhomogeneities in ventricular myocardium change dynamically with abrupt cycle length shortening. Circulation 1991;84:1333-45.
27. Han J. Ventricular vulnerability during acute coronary occlusion. Am J Cardiol 1969;24:857-64.
28. Girouard SD, Laurita KR, Pastore JM, Rosenbaum DS. Cardiac wavelength adaptation explains initiation of reentry and its prevention by d-sotalol [Abstract]. Circulation 1996;94:160.
29. Linz W, Scholkens BA, Kaiser J, et al. Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting enzyme inhibitor ramipril. Cardiovasc Drugs Ther 1989;3:873-82.
30. Rogers TB, Gaa AH, Allen IS. Identification and characterization of functional angiotensin II receptors on cultured heart myocytes. J Pharmacol Exp Ther 1986;36:438-44.
31. Susuki F, Hellmann T, Murakami K, Ludwig G. Expression of the genes for renin and angiotensinogen in tissues of the rat. Naunyn Schmiedebergs Arch Pharmacol 1987;335:R66.
32. Dzau VJ, Re RN. Evidence for the existence of renin in the heart. Circulation 1987;75:1134-6.
33. Ribuot C, Cardinal R, Godin L, et al. Prolongation by captopril of action potential duration in the normal and hypertrophied rat ventricle: direct action or inhibition of the local angiotensin converting enzyme? Cardiovasc Res 1994;28:221-7.
34. Han J, Moe G. Nonuniform recovery of excitability in venticular muscle. Circ Res 1964;14:44-60.
35. Marcus FI, Opie LH. Antiarrhythmic agents. In: Opie LH, ed. Drugs for the heart. Philadelphia: WB Saunders, 1995:207-46.
36. Sicouri S, Quist M, Antzelevitch C. Evidence for the presence of M cells in the guinea pig ventricle. J Cardiovasc Electrophysiol 1996;7:503-11.